WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor®. This move brings total upfront licensing revenue to $2 million, with additional performance-based royalties tied to product sales across both high-growth markets.
“This isn’t just an expansion—it’s execution,” said Jack Ross, CEO of Synergy CHC Corp. “Adding Turkey alongside the United Arab Emirates (UAE), compounds our momentum and unlocks untapped growth in scalable, capital-efficient markets. We’re building brand equity globally without the overhead—exactly how growth should look in 2025.”
The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor® brand—including brain health supplements, cognitive beverages, and energy shots—without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside.
Key Highlights for Investors:
With global demand for cognitive health solutions surging and strategic distribution partnerships now active, SNYR is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola’s global beverage team, reinforcing the Company’s commitment to accelerated growth and operational precision.
About Synergy CHC Corp.
Synergy CHC Corp. (NASDAQ: SNYR) is a next-generation consumer health and wellness company. Its flagship brands include FOCUSfactor®, a clinically tested brain health supplement, and Flat Tummy®, a lifestyle wellness brand for women. Synergy is executing a high-margin, global expansion strategy across functional health categories through capital-efficient partnerships.
Investor Relations
Gateway Group
Cody Slach, Greg Robles
949.574.3860
SNYR@gateway-grp.com
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…